Abstract
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have been the cornerstone for the treatment of heart failure (HF) with reduced ejection fraction for decades. According to recent and promising studies, sacubitril/valsartan (SV) might be efficient in alternative indications in the area of HF with preserved left ventricular ejection fraction, chronic kidney disease, and so on. This review briefly summarizes these promising therapeutic options regarding SV and the potential limits and pitfalls for its use in routine practice (due to cognitive uncertainties).
MeSH terms
-
Aminobutyrates / pharmacology*
-
Aminobutyrates / therapeutic use*
-
Angiotensin Receptor Antagonists / pharmacology*
-
Angiotensin Receptor Antagonists / therapeutic use
-
Angiotensin-Converting Enzyme Inhibitors / pharmacology
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Animals
-
Biphenyl Compounds
-
Drug Combinations
-
Heart Failure / drug therapy
-
Humans
-
Stroke Volume / drug effects
-
Tetrazoles / pharmacology*
-
Tetrazoles / therapeutic use*
-
Valsartan / pharmacology*
-
Valsartan / therapeutic use*
-
Ventricular Dysfunction, Left / drug therapy
Substances
-
Aminobutyrates
-
Angiotensin Receptor Antagonists
-
Angiotensin-Converting Enzyme Inhibitors
-
Biphenyl Compounds
-
Drug Combinations
-
Tetrazoles
-
Valsartan
-
sacubitril and valsartan sodium hydrate drug combination